Skip to main content

International Journal of Clinical Oncology

Ausgabe 7/2020

Including Invited Review on Central statistical monitoring

Inhalt (29 Artikel)

Invited Review Article

Central statistical monitoring of investigator-led clinical trials in oncology

Marc Buyse, Laura Trotta, Everardo D. Saad, Junichi Sakamoto

Review Article

Recent advances of the regulation roles of MicroRNA in glioblastoma

Chengrui Yan, Xiangyi Kong, Shun Gong, Fengrui Liu, Yuanli Zhao

Open Access Review Article

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy

Satoru Iwasa, Toshihiro Kudo, Daisuke Takahari, Hiroki Hara, Ken Kato, Taroh Satoh

Original Article

Implementation of a molecular tumor board at a regional level to improve access to targeted therapy

Héloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, Ingrid Felten-Vinot, Jean-Philippe Metges, Romain Corre, Thierry Lesimple, Cédric le Marechal, Lise Boussemart, Solène-Florence Kammerer-Jacquet, Edouard le Gall, Florent Denoual, Marie de Tayrac, Marie-Dominique Galibert, Jean Mosser, Julien Edeline

Original Article

Performance of three prognostic models in critically ill patients with cancer: a prospective study

Frank D. Martos-Benítez, Hilev Larrondo-Muguercia, David León-Pérez, Juan C. Rivero-López, Versis Orama-Requejo, Jorge L. Martínez-Alfonso

Original Article

A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015)

Yasumasa Nishimura, Satoshi Ishikura, Taro Shibata, Takeshi Kodaira, Yoshinori Ito, Kazuhiko Tsuchiya, Yuji Murakami, Jun-ichi Saitoh, Tetsuo Akimoto, Kensei Nakata, Michio Yoshimura, Teruki Teshima, Takashi Toshiyasu, Yosuke Ota, Kazuki Ishikawa, Hidetoshi Shimizu, Toshiyuki Minemura, Kenichi Nakamura, Masahiro Hiraoka

Original Article

Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer

C. Suzuki, N. Kiyota, Y. Imamura, J. Rikitake, S. Sai, T. Koyama, Y. Hyogo, Y. Nagatani, Y. Funakoshi, M. Toyoda, N. Otsuki, KI. Nibu, H. Minami

Original Article

Urinalysis by combination of the dipstick test and urine protein–creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer

Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito

Original Article

Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial

Yoshihiko Nakamoto, Masafumi Noda, Ryuichi Mikami, Yukihiko Tokunaga, Tatsuo Okumoto, Takashi Kawamura, Hidetoshi Fujiwara, Sadayuki Doi, Naohiro Tomita

Original Article

Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

Takashi Ohta, Takeshi Kato, Hisato Kawakami, Yasuhiro Miyake, Masahiro Goto, Shigeyoshi Iwamoto, Toshio Otsuji, Masato Nakamura, Naotoshi Sugimoto, Shu Okamura, Masahito Kotaka, Masaki Tsujie, Yukihiko Tokunaga, Hideyuki Mishima, Taishi Hata, Toshio Shimokawa, Yukinori Kurokawa, Taroh Satoh

Original Article

Serum LOX-1 is a novel prognostic biomarker of colorectal cancer

Chiyo Nakashima-Nakasuga, Shoichi Hazama, Nobuaki Suzuki, Yuki Nakagami, Ming Xu, Shin Yoshida, Shinobu Tomochika, Nobuyuki Fujiwara, Satoshi Matsukuma, Hiroto Matsui, Yukio Tokumitsu, Shinsuke Kanekiyo, Yoshitaro Shindo, Noriko Maeda, Ryouichi Tsunedomi, Michihisa Iida, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Yoshihiko Hamamoto, Hiroyuki Ogihara, Yoshinobu Hoshii, Hiroaki Nagano

Original Article

Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer

Hiroya Matsuoka, Koji Ando, Qingjiang Hu, Yoko Zaitsu, Yasuo Tsuda, Yuichi Hisamatsu, Yuichiro Nakashima, Yasue Kimura, Eiji Oki, Masaki Mori

Original Article

Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma

Zhuozhen Lyu, Mingze Ma, Yantian Xu, Xinxing Wang, Yuhua Zhu, WanHua Ren, Tao Li

Original Article

ACO2 and ANPEP as novel prognostic markers for gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas

Ziru Liu, Zhulin Yang, Li Xiong, Daiqiang Li, Qiong Zou, Yuan Yuan

Original Article

Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study

Guangdong Hou, Xi’an Li, Yu Zheng, Pengfei Liu, Fei Yan, Dongen Ju, Geng Zhang, Wanxiang Zheng, Ming Gao, Niuniu Hou, Jiarui Yuan, Fuli Wang, Jianlin Yuan

Original Article

A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables

Makito Miyake, Hideyasu Matsuyama, Satoshi Teramukai, Fumie Kinoshita, Isao Yokota, Hiroaki Matsumoto, Keiji Shimada, Mitsuru Kinjyo, Tatsuro Shimokama, Koji Okumura, Masaya Yomenori, Hideki Enokida, Masayuki Nakagawa, Yasushi Nakai, Kiyohide Fujimoto

Original Article

Atypical oncologic failure after laparoscopic and robot-assisted radical cystectomy at a single institution

Masashi Kubota, Hidetoshi Kokubun, Ritsuki Yamaguchi, Shiori Murata, Noriyuki Makita, Issei Suzuki, Ryosuke Suzuki, Yohei Abe, Yoichiro Tohi, Naofumi Tsutsumi, Yoshio Sugino, Koji Inoue, Mutsushi Kawakita

Original Article

External validation of the "optimal PSA follow-up schedule after radical prostatectomy” in a new cohort

Yoshinori Yanai, Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Hiroshi Asanuma, Mototsugu Oya

Original Article

Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer

Shuichi Morizane, Masashi Honda, Ryutaro Shimizu, Shogo Teraoka, Ryoma Nishikawa, Panagiota Tsounapi, Yusuke Kimura, Hideto Iwamoto, Katsuya Hikita, Atsushi Takenaka

Original Article

Surgical outcomes of early-stage primary vaginal nonsquamous cell carcinoma

Hidetaka Nomura, Yuji Tanaka, Makiko Omi, Sachiho Netsu, Yoichi Aoki, Terumi Tanigawa, Tomoko Kurita, Maki Matoda, Sanshiro Okamoto, Kohei Omatsu, Hiroyuki Kanao, Nobuhiro Takeshima

Original Article

Clinical significance of thermal detection of soft-tissue tumors

Akiyoshi Shimatani, Manabu Hoshi, Naoto Oebisu, Tadashi Iwai, Naoki Takada, Hiroaki Nakamura

Original Article

Management and outcome of pediatric Wilms tumor with malignant inferior Vena cava thrombus: largest cohort of single-center experience

Moatasem Elayadi, Mahmoud Hammad, Kareem Sallam, Gehad Ahmed, Soha Ahmed, Ahmed Ibrahim, Amal Refaat, Naglaa Elkinaai, Alaa Younes, Norbert Graf, Wael Zekri

Original Article

Utility of whole brain radiation therapy for leptomeningeal carcinomatosis

Yasuhiro Hirano, Kei Konishi, Yasuo Ejima

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.